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Abstract 
The molecular mechanisms leading to brain tumors still remain unclear. Nevertheless, there is 
increasing evidence that epigenetic effects play crucial roles in tumor development and progres-
sion. Thereby, 5-hydroxymethylcytosine (5hmC) represents a further base modification of cyto-
sine besides 5-methylcytosine (5mC). In addition to the role of 5hmC as an intermediate in de-
methylation, 5hmC is of reasonable importance for cellular control. Previous studies showed that 
loss of 5hmC is a hallmark of human malignancies, e.g. in glioma, melanoma, and myeloid tumors. In 
myeloid malignancies studies showed that loss of 5hmC was due to mutations within 
ten-eleven-translocation (TET) genes, enzymes being responsible for conversion of 5mC to 5hmC. 
Nevertheless, till date there are no genetic characterization data of TET enzymes available for 
glioma.  
In this study, we genetically characterized TET2 and TET3 alterations in 50 human gliomas 
(WHO-Grade II-IV) and in 19 healthy brain samples. We identified 7 genetic alterations within 
TET2 (p.V218M, p.G355N, p.P363L, p.L1721W, p.P1723S, p.I1762V, p.H1778R). Additionally, we 
performed quantification of 5hmC amount and added functional prediction analysis of identified 
TET alterations to evaluate the biological impact of these alterations on the hydroxymethylome. 
An analysis of TET3 showed no non-synonymous alterations.  
In summary, we did not find correlations of TET alterations with 5hmC amount. Thus, our data 
emphasize that, in contrast to leukemia, loss of 5hmC in glioma is not caused by TET gene al-
terations. Moreover, other disturbances, such as disrupted gene expressions or functional inhi-
bitions of TET proteins may be responsible for the aberrant epigenome of human glioma. 
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Introduction 
The mechanisms leading to human brain tumors 
still remain unclear. Nevertheless, there is strong ev-
idence that epigenetic changes significantly contribute 
to tumor development and progression [1-6]. One 
prominent example of an epigenomic hallmark that is 
highly relevant in human glioma is the silencing of 
O6-methylguanine DNA-methyltransferase (MGMT) 
[1] by promoter methylation. This phenomenon has 
been described as a strong predictive factor of treat-








cytoma (AA) and glioblastoma (GBM) [5].  
In the recent years, a new base modification be-
sides 5-methylcytosine (5mC) has been described: 
5-hydroxymethylcytosine (5hmC) [7]. Till date, the 
distinct function of 5hmC still remains unclear but 
there is evidence, that 5hmC is involved in gene reg-
ulation, developmental control and active demethyla-
tion processes [8-10]. Whereas 5mC is generated out 
of cytosine (C) by DNMT (DNA methyltransferase) 
enzymes, 5hmC is converted of 5mC by the TET 
(ten-eleven-translocation) enzymes [8]. After the gen-
eration, 5hmC can be further converted to 
5-formylcytosine (5fC) and 5-carboxycytosine (5caC) 
by the TET enzymes and finally decarboxylated by 
TDG (thymine-DNA glycosylase) to unmodified C [8]. 
This sequence of modifications describes an active 
demethylation pathway of methylated cytosine [8].  
Besides the role as an intermediate in active de-
methylation pathways, other studies showed that 
5hmC also states a functional importance in gene 
regulation [10, 11]: Spruije et al. showed that there are 
dynamic readers for 5mC and 5hmC that recognize 
either 5mC or 5hmC [10]. Interestingly, these readers 
change during cellular differentiation from embryonic 
stem cell (ESC) state to neuronal progenitor cells 
(NPC), and adult brain tissue [10]. There are also dif-
ferences of 5hmC amount detectable depending on 
the investigated tissue type and on age [9, 12, 13], 
emphasizing the complexity and plasticity of the 
epigenome. 
Whereas human brain tissue exhibits high 
amounts of 5hmC, there is a loss of 5hmC in brain 
tumors leading to a disturbance of the hy-
droxymethylome [12]: In contrast to normal human 
brain tissue, that exhibits up to 1.1 % 5hmC of all cy-
tosines, brain tumors and especially highly malignant 
WHO-Grade IV glioblastoma (GBM) exhibit only 
vanishingly low amounts of 5hmC (mean amounts of 
0.078 % 5hmC of all cytosines) [12].  
Besides brain tumors, a similar phenomenon has 
also been described for other malignancies, e.g. mel-
anoma, oral squamous cell carcinoma and myeloid 
malignancies [14-19]. Thereby, studies revealed that 
TET2 mutations are accompanied by decreased 5hmC 
amounts [20]. In a wide range of myeloid neoplasms, 
such as chronic myelomonocytic leukemia, acute my-
eloic leukemia and myelodysplastic syndrome, het-
erozygous deletions and mutations of TET2 were 
found in high frequencies [16, 21-24]. Furthermore, 
functional studies revealed that the loss of 5hmC in 
these tumor entities is directly caused by TET2 muta-
tions within the functional domains of the TET2 pro-
tein [15-17, 20].  
Till date, there are no comparable studies avail-
able investigating the significance of TET mutations in 
glioma by validating the consequences of TET muta-
tions on glioma 5hmC amount. This problem is now 
addressed by us. Therefore, this is the first compre-
hensive study that genetically characterizes TET al-
terations in the context of human glioma by direct 
sequencing of the TET2 and TET3 genes. Thus, the 
data generated in this approach are of fundamental 
importance to better understand the role of TET pro-
teins in the context of brain tumor formation and they 
will help to better understand the molecular mecha-
nisms leading to disruption of the glioma epigenome.  
In this study, we investigated 50 human glioma 
of WHO-Grades II to IV and genetically characterized 
TET2 and TET3 sequence alterations. Additionally, 
we sequenced the TET2 and TET3 genes in 19 human 
control brain samples. Furthermore, we quantified 
5hmC amount in all 69 investigated tissue specimen 
and correlated 5hmC amount with TET mutations. A 
prediction analysis of the functional effects of identi-
fied TET alterations was performed using the Poly-
Phen-2 algorithm in order to evaluate the biological 
significance of identified TET alterations.  
Materials and Methods 
Sample collection 
In the current study, we investigated 69 different 
tissue specimen including 50 glioma samples 
(WHO-Grade II-IV) and 19 brain tissue samples as 
unaffected control brain tissue. 
All tumor samples were provided by the Brain 
Tumor Bank of the Center for Neuropathology. Writ-
ten informed consent was obtained according to the 
guidelines of the local ethics committee. The surgical 
tumor samples used in this study were snap-frozen 
and stored at -80°C. Routine histological procedures 
included H&E (Haematoxylin and Eosin), EvG (Elas-
tica van Gieson), PAS (Periodic acid-Schiff), Gomori 
silver stain as well as immunohistochemistry using 
antibodies against GFAP (glial fibrillary acidic pro-
tein, monoclonal mouse antibody, clone 6F2, Dako), 
MAP2 (microtubule-associated protein 2, clone HM.2, 
Sigma) and Ki67 proliferation associated antigen 
(monoclonal mouse antibody, clone MIB1, Dako). 
Routine diagnostics was performed on tumor tissue 
that has been formalin-fixed (4 % buffered formalin) 
and paraffin embedded. All tumor samples were 
classified according to the current WHO (world 
health organization) classification of tumors of the 
central nervous system, 4th edition, 2007 [25-27]. Mean 
age of patients was 53 years. The female to male ratio 
was 13 to 37. Detailed information of patients can be 
found in Table 1. 
Brain tissue specimen that served as control 
samples were provided by the Neurobiobank Munich 




(NBM) and were collected and clinically as well as 
neuropathologically characterized according to the 
standard protocols of the NBM established by Brain-
Net Europe and BrainNet Germany. Written informed 
consent was obtained according to the guidelines of 
the local ethics committee. Mean age of patients was 
64 years. The female to male ratio was 8 to 11. De-
tailed information on patients can be found in Table 
2. 
Molecular genetic characterization of gliomas 
Determinations of IDH1 (isocitrate dehydro-
genase 1) and IDH2 (isocitrate dehydrogenase 2) mu-
tations were performed using the pyrosequencing 
technique as described previously [12, 28]. To detect 
IDH1 mutations, we amplified a 88 bp long DNA 
fragment that includes the mutation hot spot at codon 
132 using the primer pair 5'-biotin-AAAAATATC 
CCCCGGCTTG-3' and 5'-TGCCAACATGACTTA 
CTTGATCC-3' and the sequencing primer 
5'-TGATCCCCATAAGCA-3'. To detect IDH2 muta-
tions, we amplified a 83 bp long DNA fragment in-
cluding the mutation hot spot at codon 172 using the 
primer pair 5'-TCCCACGCCTAGTCCCTG-3' and 
5'-biotin-CTCTCCACCCTGGCCTACC-3' and the 
sequencing primer 5′-AGCCCATCACCATTG-3′. 
MGMT promoter methylation was determined as 
described previously [29]. DNA was bisulfite treated 
using the EpiTect Bisulfite kit (Qiagen, Hilden Ger-
many) according to the manufacturer’s protocol. Af-
terwards, we performed methylation specific PCR 
(MSP) and Sanger sequencing. MSP was performed 
using the primer pair 5'-TTTGTGTTTTGATG 
TTTGTAGGTTTTTGT-3' and 5'-AACTCCACACTC 
TTCCAAAAACAAAACA-3' for amplification of the 
unmethylated promoter region and the primer pair 
5'-TTTCGACGTTCGTAGGTTTTCGC-3' and 
5'-GCACTCTTCCGAAAACGAAACG-3' for amplifi-
cation of the methylated promoter region. Sanger se-
quencing of the MGMT promoter region was per-
formed by amplifying a 316 bp long PCR product that 
covers 25 CpGs using the primer pair 
5’-ATGTTGGGATAGTTCGCGTTTTTAGA-3’ and 
5’-CCAATCCACAATCACTACTTC-3’. As described 
previously we considered the MGMT promoter as 
methylated if more than half of the CpGs were meth-
ylated (i.e. 13 of 25), as partially methylated if 9 to 12 
CpGs were methylated and as unmethylated if less 
than 9 CpGs were methylated [29]. LOH1p/19q (loss 
of heterozygousity of chromosome 1p and 19q) was 
detected as described previously [30]. In brief, we 
used the 5 microsatellite markers D1S1608, D1S548, 
D1S1592, D1S1184, and D1S1161 for the short arm of 
chromosome 1 (1p) and the 5 microsatellite markers 
D19S433, D19S431, D19S718, D19S559, and D19S601 
for the long arm of chromosome 19 (19q). PCR am-
plicons of microsatellite markers were subsequently 
loaded onto high resolution SYBR Gold gels for in-
terpretation [30].  
DNA extraction  
Representative H&E stained cryo-slides were 
prepared and microscopically assessed. For further 
analysis, only samples with solid, viable tumor con-
sisting of at least 90% tumor cells were included. DNA 
extraction was performed on 50 mg of micro-dissected 
tumor tissue. In case of control brain tissue, 50 mg of 
frozen brain tissue was used in this study. DNA ex-
tractions were performed using the QIAamp DNA 
Micro Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol.  
Polymerase chain reaction (PCR) 
PCR was performed using the HotStarTaq DNA 
Polymerase Master Mix Kit (Qiagen, Hilden, Germa-
ny) according to the manufacturer’s protocol and 
standard PCR setups. In order to identify TET2 muta-
tions, we used the primers published by Delhommeau 
et al. [16], in order to identify TET3 mutations, we 
used the primers published by Abdel-Wahab et al. 
[15], respectively. 
Sequencing analysis 
Sequencing reactions of PCR amplified DNA 
fragments were performed using standard protocols. 
In brief we purified PCR fragments using the QI-
Aquick PCR Purification Kit (Qiagen, Hilden, Ger-
many) and performed a subsequent amplification 
using the BigDye Terminator V3.1 Cycle Sequencing 
kit (life technologies, Carlsbad, USA). The product 
was purified using the DyeEX 2.0 Spin Kit (Qiagen, 
Hilden, Germany) and sequenced on a 3130 Genetic 
Analyzer (life technologies, Carlsbad, USA). Data 
analysis was performed using SeqScape Software (life 
technologies, Carlsbad, USA), ApE 
(http://biologylabs.utah.edu/jorgensen/wayned/ap
e/) and Chromas Lite (http://technelysium. 
com.au/). Functional effects of identified alterations 
were analysed using PolyPhen-2 algorithm [31]. 
Quantification of 5hmC amount 
Quantification of 5hmC amount was performed 
as described previously [9, 12]. In brief, 4 µm FFPE 
(formaline-fixed, paraffin-embedded) tissue slides 
were deparaffinized and treated with 2N HCl. After 
pre-incubation with 3% I-Block Protein-Based Block-
ing Reagent (Applied Biosystems, Darmstadt, Ger-
many) sections were incubated with polyclonal rabbit 
anti-5-hydroxymethylcytosine antibody (1:1,000, Ac-
tive Motif, Rixensart, Belgium) for 18 hours at 4°C. 
Afterwards, sections were treated with Super Sensi-




tive Polymer-HRP Detection System (BioGenix, San 
Ramon, USA), followed by incubation in DAB 
(3,3’-diaminobenzidine) and counter stained using 
hemalum. Quantification of positive nuclei was per-
formed using an Olympus BX50 microscope (Olym-
pus, Tokyo, Japan) and a Color View III camera sys-
tem (Soft Imaging System, Münster, Germany) using 
10x and 20x objectives (Olympus, Tokyo, Japan). 
Representative areas without technical artefacts were 
selected for quantifications.  
Results 
Genetic Analysis of Ten-Eleven-Translocation 
2 and 3 in Glioma  
In this study, we analysed 50 human glioma of 
WHO-Grades II-IV, including 3 WHO-Grade II glio-
mas, 10 WHO-Grade III gliomas and 37 WHO-Grade 
IV glioblastomas (GBM) on genetic alterations of the 
TET2 and TET3 genes. Sequencing was performed by 
a step-wise approach, including (1) an exploratory set, 
(2) a validation set and (3) a verification set (Table 1). 
Glioma samples were randomly matched to the three 
test sets. Samples of the exploratory set were sub-
jected to complete sequencing of TET2 or TET3, re-
spectively, samples of the validation set were sub-
jected to sequencing of only genomic fragments that 
showed alterations in the exploratory set, and samples 
of the verification set were subjected to targeted 
re-sequencing of most abundant genetic variations of 
the exploratory and validation set.  
Using this approach, we identified 5 different 
TET2 (p.V218M, p.G355N, p.P363L, p.L1721W, 
p.I1762V) variants in 21 glioma samples (Table 1, 
Figure 1). 29 gliomas did not show TET2 alterations. 
Interestingly, no variant was located within one of the 
two conserved domains of TET2 (Figure 2). The most 
frequent alteration was the p.I1762V exchange that 
occurred in 50 % of all alterations. Further details on 
the distribution of alterations can be found in Figure 
3a. 
An analysis of TET3 showed three glioma sam-
ples with synonymous p.L711L alterations. We did 
not identify any non-synonymous alterations within 
TET3. 
Genetic Analysis of Ten-Eleven-Translocation 
2 and 3 in Brain Tissue  
To evaluate the frequency of identified TET al-
terations in healthy human brain tissue, we per-
formed an equivalent analysis as performed in case of 
glioma using 19 human control brain samples.  
In case of TET2 we found 5 different TET2 vari-
ants (p.G355N, p.L1721W, p.P1723S, p.I1762V, 
p.H1778R) within 13 control brain samples (Table 2). 
Six controls did not show any TET2 alterations. No 
variant was located within one of the two conserved 
domains of TET2 (Figure 2). In control tissue, the 
p.I1762V exchange was the most frequent variation 
that was found in 61 % of all alterations. Further de-
tails on the distribution of alterations can be found in 
Figure 3b. 
An analysis of TET3 showed one control sample 
with a synonymous p.L711L. We did not identify any 
non-synonymous alterations within TET3. 
Table 1. Detailed information on glioma samples used in this study. We included 50 glioma patients in our study, including three patients 
with WHO-Grade II glioma, ten patients with WHO-Grade III glioma and 37 patients with WHO-Grade IV glioblastoma. The mean age 
of patients was 53 years. The female to male ratio was 13 to 37. MGMT promoter methylation: 0: unmethylated; 1: methylated; 2: partially 
methylated; 3: not analysable; 9: not analysed; IDH1 and IDH2 mutation status: 0: IDH1 no mutation, IDH2 no mutation; 1: IHD1 mu-
tation, IDH2 no mutation; 2: IDH1 no mutation, IDH2 mutation; 3: IDH1 mutation, IDH2 mutation; 9: not analysed; LOH 1p/19q status: 
0: no LOH 1p/19q; 1; partial LOH 1p; 2: partial LOH 19q; 3: LOH 1p/19q; 4: isolated partial LOH 1p; 5: isolated partial LOH 19q; 6: other 
aberration; 9: not analysed; TET2 and TET3 analysis: 1: exploratory set; 2: validation set; 3: verification set; 9: not analysed. 









































2 m 59 Diffuse Astrocytoma II 9 1 9 11.80 2 9 c.5284A>G p.I1762V - - 
3 m 32 Protoplasmatic Astrocyto-
ma 
II 9 1 9 3.89 2 9 c.5284A>G p.I1762V - - 
4 m 36 Anaplastic Oligodendro-
glioma 
III 9 0 2 8.59 2 9 c.5284A>G p.I1762V - - 





6 m 53 Anaplastic Astrocytoma III 0 0 0 3.63 1 9 c.5284A>G p.I1762V - - 
7 m 45 Anaplastic Astrocytoma III 9 1 0 1.59 2 9 - - - - 





9 m 33 Anaplastic Astrocytoma III 9 1 9 11.80 2 9 c.5284A>G p.I1762V - - 









11 m 24 Anaplastic Astrocytoma III 2 1 0 5.09 2 9 c.5162T>G p.L1721W - - 
12 m 26 Anaplastic Astrocytoma III 1 1 0 3.58 2 9 c.5284A>G p.I1762V - - 
13 m 62 Anaplastic Astrocytoma III 1 1 0 16.93 2 9 c.5284A>G p.I1762V - - 
14 f 67 Glioblastoma with oligo 
component 
IV 0 0 9 0.56 1 9 c.5162T>G p.L1721W - - 
15 m 65 Glioblastoma IV 0 0 5 3.48 1 1 c.5284A>G p.I1762V c.2131T>C p.L711L 
16 f 69 Glioblastoma IV 0 0 6 0.25 1 1 - - - - 
17 m 39 Glioblastoma IV 0 0 0 1.33 1 1 c.5284A>G p.I1762V - - 
18 m 54 Glioblastoma IV 1 0 0 0.08 2 1 c.5284A>G p.I1762V c.2131T>C p.L711L 
19 m 64 Glioblastoma IV 1 0 4 0.97 2 1 c.5284A>G p.I1762V c.2131T>C p.L711L 







21 f 64 Glioblastoma IV 2 0 0 1.61 2 9 c.5284A>G p.I1762V - - 
22 m 68 Glioblastoma IV 1 0 0 17.26 2 9 - - - - 
23 m 54 Glioblastoma IV 0 0 9 0.37 3 9 - - - - 
24 m 73 Glioblastoma IV 0 0 0 0.37 3 9 - - - - 
25 m 62 Glioblastoma IV 0 9 0 3.23 3 9 c.1064G>A  p.G355N - - 
26 m 63 Glioblastoma IV 1 0 0 0.00 3 9 - - - - 
27 f 65 Glioblastoma IV 3 1 0 0.74 3 9 - - - - 
28 m 70 Glioblastoma IV 1 0 0 1.82 3 9 - - - - 
29 m 39 Glioblastoma IV 0 0 0 0.29 3 9 - - - - 
30 m 52 Glioblastoma IV 2 9 2 1.82 3 9 - - - - 
31 m 49 Glioblastoma IV 0 9 9 0.10 3 9 - - - - 
32 m 78 Glioblastoma IV 1 0 0 0.00 3 9 - - - - 
33 m 75 Glioblastoma IV 1 9 0 1.22 3 9 - - - - 
34 m 65 Glioblastoma IV 0 0 0 3.33 3 9 - - - - 
35 f 45 Glioblastoma IV 0 0 6 4.32 3 9 - - - - 
36 m 64 Glioblastoma IV 1 0 1 2.35 3 9 - - - - 
37 m 72 Glioblastoma IV 1 0 0 0.59 3 9 - - - - 
38 f 60 Glioblastoma IV 2 0 0 0.16 3 9 - - - - 
39 m 54 Glioblastoma IV 0 0 4 1.10 3 9 - - - - 
40 f 48 Glioblastoma IV 1 0 0 3.56 3 9 - - - - 
41 m 37 Glioblastoma IV 1 0 1 0.58 3 9 - - - - 
42 m 50 Glioblastoma IV 1 0 3 0.16 3 9 - - - - 
43 f 50 Glioblastoma IV 0 0 4 0.49 3 9 - - - - 
44 m 56 Glioblastoma IV 1 0 4 0.78 3 9 - - - - 
45 f 9 Glioblastoma IV 1 0 4 0.04 3 9 - - - - 
46 f 33 Glioblastoma IV 0 0 0 0.32 3 9 - - - - 
47 m 56 Glioblastoma IV 0 0 0 0.02 3 9 - - - - 
48 m 68 Glioblastoma IV 0 0 2 0.01 3 9 - - - - 





50 m 73 Glioblastoma IV 2 0 3 0.00 3 9 - - - - 
 
Table 2. Detailed information on control samples used in this study. We included 19 control brain samples with mean age of 64 years. 
The female to male ratio was 8 to 11. TET2 and TET3 analysis: 1: exploratory set; 2: validation set; 3: verification set; 9: not analysed. 
Case Sex Age 
[y] 
5hmC posi-











TET3 variation in amino 
acid sequence 
1 f 46 84.38 1 1 c.5284A>G p.I1762V c.2131T>C p.L711L 
2 f 58 41.11 1 1 c.5284A>G p.I1762V - - 
3 f 40 79.66 2 9 c.5162T>G, c.5284A>G p.L1721W, p.I1762V - - 
4 m 60 81.21 2 9 c.5284A>G p.I1762V - - 
5 m 87 54.32 2 9 c.5167C>T, c.5333A>G p.P1723S, p.H1778R - - 
6 m 61 55.46 2 9 - - - - 
7 f 85 55.05 2 9 c.5284A>G p.I1762V - - 
8 m 46 64.29 2 9 - - - - 
9 f 77 82.21 2 9 c.5162T>G, c.5284A>G p.L1721W, p.I1762V - - 
10 m 74 83.41 2 9 c.5284A>G p.I1762V - - 
11 f 83 80.33 2 9 c.5284A>G p.I1762V - - 
12 f 77 81.32 3 9 - - - - 
13 m 75 77.77 3 9 - - - - 
14 m 63 82.14 3 9 - - - - 
15 m 53 83.11 3 9 - - - - 
16 m 71 86.66 3 9 - - - - 
17 f 55 78.89 3 9 - - - - 
18 m 60 84.19 3 9 - - - - 
19 m 54 54.17 3 9 c.1064G>A  p.G355N - - 
 





Figure 1. Representative electropherograms of TET2 sequencing. Identification of alterations was performed by classical dideoxy sequencing. Thereby, sequencing of both the 
forward and reverse strand was performed. As representative electropherograms, the sequencing analysis of TET2 gene of glioma sample # 5 (anaplastic astrocytoma, 
WHO-Grade III) (a, b) is shown. There is a heterozygous position within the TET2 sequence (red box) both in the forward (a) and reverse (b) sequencing analysis. This 
heterozygous position corresponds with position 1088 of the DNA sequence and results in a CCT to CTT exchange (c.1088C>T) (a). After translation there is a proline (P) to 
leucine (L) exchange in the amino acid sequence resulting in a p.P336L mutation of TET2. The analysis of the reverse strand confirms the identified heterozygosity at position 1088 
(AAG to AGG exchange in the reverse complement sequence corresponding to a CTT to CCT exchange in the forward sequencing reaction). Representative electropherograms 
of the sequencing analysis of a control sample (control case # 5) shows that there is no sequence variation at position 1088 (blue box) in the forward (c) and reverse (d) 
sequencing analysis of the TET2 gene. Electropherograms: black peaks represent guanine (G), blue peaks represent cytosine (C), green peaks represent adenine (A) and red peaks 
represent thymine (T). RF: reference sequence. ID: identifier of base position in gene. 
 
Figure 2. Overview of identified variants within the coding region of TET2. Sequencing of 50 glioma and 19 controls revealed 28 TET2 variants in glioma and 13 variants in 
controls. Interestingly, most variants accumulate within two short fragments of TET2 (355-363 and 1723-1778). There are no alterations within the 2 conserved domains. 
Indicated is the coding region of TET2 (exons 3 to 11). Conserved domains 1 and 2 are shown in yellow. Variants occurring in glioma are indicated by red marks, variants 
occurring in controls are indicated by blue marks. 





Figure 3. Frequency of TET2 variants in glioma and controls. a) In glioma we identified 5 different TET2 variants (p.V218M, p.G355N, p.P363L, p.L1721W, p.I1762V) with 
p.I1762V being most frequent one. b) In control tissue, we identified 5 different TET2 variants (p.G355N, p.L1721W, p.P1723S, p.I1762V, p.H1778R) with p.I1762V being the 
most frequent variant.  
 
 
Quantification of 5hmC Amount and Evalua-
tion of Functional Effects of Identified Altera-
tions 
In order to evaluate the biological relevance of 
TET alterations identified in glioma we quantified the 
amount of 5hmC in all 50 investigated glioma and in 
all 19 healthy control samples. 
Using immunohistochemistry (IHC) and specific 
antibodies against 5hmC we found that glioma almost 
stain negative for 5hmC (Figure 4a). These data are in 
good correlation with our previous findings [12, 32]. 
In contrast to this finding, healthy brain tissue shows 
numerous 5hmC positive cells (Figure 4b). These data 
also correlate well with our previous findings [9, 12]. 
The quantification of 5hmC amount in all 69 samples 
revealed mean amounts of 2.88 % 5hmC positive cells 
in glioma and 73.14 % 5hmC positive cells in healthy 
brain tissue (p < 0.0001, unpaired t-test, Figure 4c).  
A sample specific comparison of the presence of 
TET2 alterations with the amount of 5hmC did not 
show correlations of 5hmC amounts and TET2 altered 
gliomas on individual level (Figure 5a). In healthy 
brain samples, there was no sample specific correla-
tion of low 5hmC amounts and TET2 alterations 
(Figure 5b).  
In order to determine the general effect of TET2 
alterations on 5hmC amounts, we next performed 
alteration-specific analysis of 5hmC amounts. We 
found that there were no general correlations of TET2 
alterations and low 5hmC amounts: TET2 wild type 
(wt) glioma showed mean amounts of 1.50 % 5hmC 
positive cells (Figure 6a). Glioma with the TET2 
p.V218M alteration (one sample) showed 0.02 % 
5hmC positive cells, glioma with the p.G355N altera-
tion (five samples) showed mean amounts of 3.68 % 
5hmC positive cells, glioma with the p.P363L altera-
tion (one sample) showed 5.27 % 5hmC positive cells, 
glioma with the p.L1721W alteration (seven samples) 
showed mean amounts of 4.21 % 5hmC positive cells 
and glioma with the p.I1762V alteration (14 samples) 
showed mean amounts of 5.10 % 5hmC positive cells 
(Figure 6a). In control tissue, TET2 wild type samples 
showed mean amounts of 77.10 % 5hmC positive cells 
(Figure 6b). Samples with the TET2 p.G355N altera-
tion (one sample) showed 54.17 % 5hmC positive 
cells, samples with the p.L1721W alteration (two cas-
es) showed mean amounts of 80.94 % 5hmC positive 
cells, cases with the p.P1723S alteration (one sample) 
showed 54.32 % 5hmC positive cells, cases with the 
p.I1762V alteration (eight cases) showed mean 
mounts of 73.42 % 5hmC positive cells and cases with 
the p.H1778R alteration (one case) showed 54.32 % 
5hmC positive cells (Figure 6b). Comparing the 
amount of 5hmC in all TET2 wild type glioma with 
the amount of 5hmC in all TET2 altered glioma 
showed slightly increased amounts of 5hmC in glio-
ma with TET2 alteration (Figure 6c). A comparison of 
the 5hmC amounts in all healthy brain tissue without 
TET2 alteration with the samples with TET2 alteration 
showed slightly decreased amounts of 5hmC in sam-
ples with TET2 alteration (Figure 6c).  
Additionally, we performed a prediction analy-
sis of functional effects using the PolyPhen-2 (Poly-
morphism Phenotyping v2) algorithm via the online 
web server [31]. The PolyPhen-2 software predicts the 
possible impact of amino acid substitutions on the 
function and stability of human proteins by the use of 
structural and comparative evolutionary considera-
tions [31]. Thereby, the algorithm estimates the 
probability of missense mutations to be damaging and 
integrates the UCSC Genome Browser’s human ge-
nome annotations and MultiZ multiple alignments of 
vertebrate genomes with the human genome [31]. 
After processing a query, PolyPhen-2 reports a score 
ranging from 0 to 1 indicating the likelihood of a 
functional effect of the analysed mutation. Thereby, 
low scores (near 0) indicate that the mutations is likely 




to be not of functional importance (“benign”) while 
high scores (near 1) indicate that the mutation is likely 
to be of functional importance (“possibly damaging” or 
“probably damaging”) [31]. 
The analysis showed that the p.V218M variant 
found in 2 % of glioma has a predicted “benign” effect 
(PolyPhen-2 score 0.000) (Table 3). The p.G355N var-
iant that we found in 10 % of glioma has a predicted 
“possibly damaging” effect (PolyPhen-2 score 0.795). 
The p.P363L variant that we found in 2 % of glioma 
has a predicted “benign” effect (PolyPhen-2 score 
0.0421). The p.L1721W variant that we found in 14 % 
of glioma has a predicted “possibly damaging” effect 
(PolyPhen-2 score 0.794). The p.I1762V variant that we 
found in 28 % of glioma has a predicted “benign” ef-
fect (PolyPhen-2 score 0.012).  
 
 
Figure 4. Quantification of 5hmC amount in glioma and control tissue. Using specific antibodies against 5hmC we see only very few positively stained cells in human glioma 
samples (a) but numerous positively stained cells in healthy control brain tissue (b). Quantification of 5hmC positive cells in all 50 glioma and 19 control samples reveals a 
significant loss of 5hmC in glioma (mean of 2.88 % 5hmC positive cells) compared to healthy brain tissue (mean of 73.14 % 5hmC positive cells, p < 0.0001, unpaired t-test). These 
results are well in line with our previous findings [12, 32]. Indicated are mean and standard error of the mean (SEM). Scale bar: 200µm. 
 
Figure 5. 5hmC amount in all 69 investigated specimens. Bar graph representing the individual amounts of 5hmC positive cells in all 50 glioma samples (a) and in all 19 control 
samples (b). Additionally, the case numbers and all identified TET2 alterations are indicated at the bottom of the bar graphs. Interestingly, the amount of 5hmC is independent of 
TET2 alterations. wt: wild type. 





Figure 6. Analysis of 5hmC amount depending on distinct TET2 alterations. An analysis of the 5hmC amount in glioma without TET2 alteration (wt) and with the TET2 
alterations p.V218M, p.G355N, p.P363L, p.L1721W and p.I1762V demonstrate that TET2 alterations are not associated with decreased amounts of 5hmC (a). Analysing the 
amount of 5hmC in control brain tissue without TET2 alterations (wt) and with the TET2 alterations p.G355N, p.L1721W, p.P1723S, p.I1762V and p.H1778R, we do not find that 
TET2 alterations are associated with a statistically significant loss of 5hmC (b). A comparison of 5hmC amount in TET2 wild type glioma with the amount of 5hmC in all TET2 
altered glioma shows slightly increased amount of 5hmC in TET2 altered glioma (c). In healthy brain tissue, we see slightly decreased amounts of 5hmC in specimens with TET2 
alterations compared with TET2 wild type specimens (c). Indicated are mean and standard error of the mean (SEM). wt: wild type. 
 
Table 3. Analysis of functional effects of identified glioma-associated alterations. Using the PolyPhen-2 algorithm we analysed the func-
tional effect of all identified glioma-associated TET2 alterations. Indicated are the frequencies of all identified variants in glioma and control 
tissue as well as the evaluation of the biological effect of the variants using the PolyPhen-2 algorithm. 
Variation Frequency in glioma Frequency in controls PolyPhen-2 analysis of variation 
 p.V218M  2 % (1/50) 0 % (0/19) benign (0.000) 
 p.G355N 10 % (5/50) 5.26 % (1/19) possibly damaging (0.795) 
p.P363L 2 % (1/50) 0 % (0/19) benign (0.0421) 
p.L1721W 14 % (7/50) 10.53 % (2/19) possibly damaging (0.794) 




Human gliomas are characterized by a disturbed 
epigenomic landscape [12, 32]. Especially in the con-
text of 5hmC, a further base modification of cytosine 
besides 5mC, high grade glioma (WHO-Grade III and 
IV) show a tremendous loss of 5hmC compared to 
normal brain tissue [12, 32]. Till date, the causal 
mechanisms leading to this disturbance remain un-
clear [12, 32].  
5hmC is generated out of 5mC and can be further 
converted to 5fC and 5caC representing an active 
demethylation pathway [8]. These steps are catalyzed 
by the ten-eleven-translocation methylcytosine diox-
ygenases TET [8]. Thus, a disturbance of the conver-
sion of 5mC to 5hmC may explain the loss of 5hmC in 
glioma. 
In 2011, Xu et al. described that the al-
pha-ketoglutarate (aKG) dependent dioxigenases TET 
can be competitively inhibited by 2-hydroxyglutatrate 
(2-HG) [33]. As mutations of the iso-
citrate-dehydrogenases (IDH) lead to the production 
of 2-HG it is likely that tumors with IDH mutations 
show a loss of 5hmC due to inhibition of TET enzyme 
activity. In WHO-Grade II and III gliomas, 
IDH-mutations are frequent events, thus these 
IDH-mutations may explain the loss of 5hmC in 
WHO-Grade II and III glioma. Investigations exam-
ining the effect of IDH-mutations and the amount of 
5hmC revealed that, indeed, IDH mutations result in 
decreased levels of 5hmC in WHO-Grade II diffuse 
astrocytoma and WHO-Grade III anaplastic astrocy-
toma [12]. But in WHO-Grade IV glioblastoma (GBM) 
there was no correlation of IDH-mutation status and 
amount of 5hmC detectable [12, 32]. Furthermore, 
GBMs show even lower amounts of 5hmC compared 
with WHO-Grade II and III glioma [12]. This empha-
sizes, that there are other disturbances occurring in 
IDH unmutated glioma that result in a loss of 5hmC. 
One possible explanation might be an inappro-
priate function of TET enzymes due to mutations. 
Recent research in myeloid malignancies showed that 
there is indeed an associated of TET mutations with 
the loss of 5hmC [15-17]: Heterozygous deletions and 
mutations of TET2 were found in a wide range of 
myeloid cancers, such as chronic myelomonocytic 
leukemia, acute myeloic leukemia and myelodysplas-
tic syndrome [16, 21, 22]. Additionally, studies re-
vealed that TET2 mutations are accompanied with 
decreased 5hmC amounts [20]. As glioma also show a 
reduction of 5hmC amounts, the question rises if this 
tremendous loss of 5hmC in glioma is caused by TET 




mutations similar to the phenomenon observed in 
myeloid tumors. But till date, there are no sequencing 
data available for TET enzymes in human glioma. 
Thus, this study is of fundamental importance repre-
senting the first comprehensive analysis addressing 
this question in human glioma. 
Our genetic characterization of TET2 and TET3 
alterations in 50 glioma samples and 19 control brain 
samples revealed that, indeed TET2 alterations occur 
in glioma but the comparison with control tissue 
showed, that there are also genetic alteration in 
healthy brain tissue (Figure 3). Additionally, no iden-
tified variant was located within the conserved do-
mains 1 or 2 of TET2 (Figure 2). There were no 
non-synonymous alterations within TET3. Addition-
ally, we quantified the amount of 5hmC in glioma and 
control specimens and found that glioma exhibited 
significantly reduced amounts of 5hmC compared 
with healthy brain tissue (Figure 4). These results are 
well in line with our previous findings [12, 32]. A 
correlation of 5hmC amount with identified TET2 
alterations demonstrated that TET2 alterations are not 
associated with low 5hmC amounts (Figures 5 and 6). 
These findings emphasize that in glioma – contrasting 
the findings in myeloid malignancies [15, 16, 34, 35] – 
TET mutations are not causal for the loss of 5hmC. 
Thus, other molecular events may occur in glioma 
leading to the decrease of 5hmC amounts in brain 
tumors. One possible mechanism may be a nuclear 
exclusion of TET proteins in glioma. Müller et al. de-
scribed that nuclear exclusion of TET1 is associated 
with low amounts of 5hmC in some tumors [36]. 
However, till date there are no localization studies for 
TET2 and TET3 available that investigate, if there is a 
nuclear exclusion of TET2 and TET3 in glioma that 
might explain low amounts of 5hmC. Additionally, 
the TET2 alterations found in the current study may 
also influence the localization of the TET2 protein. 
However, additional studies analysing the functional 
consequences of TET2 alterations on the cellular lo-
calization of the protein will be necessary. 
Another possible mechanism affecting the 5hmC 
amount in glioma might be a reduced TET gene ex-
pression resulting in lower amounts of functional 
protein in glioma. As TET proteins are responsible for 
the conversion of 5mC to 5hmC [8], reduced tran-
scription levels of TET may result in decreased 5hmC 
amounts. Lian et al. addressed this question in ma-
lignant melanoma and found that loss of 5hmC can be 
explained by decreased expressions of TET genes [14] 
in skin tumors: Whereas TET1, TET2 and TET3 are 
highly transcribed in nevi, all three genes are signifi-
cantly down-regulated in malignant melanoma. These 
data demonstrate that additional studies will be nec-
essary that investigate TET gene expression levels in 
glioma. 
Further possible mechanism that may be re-
sponsible for the loss of 5hmC might be a decreased 
TET enzyme activity (independent of IDH mutations), 
an inhibition of DNA accessibility for TET enzymes 
due to aberrant DNA occupancy or an increased de-
methylation rate disturbing the homeostasis between 
methylation and demethylation processes.  
In summary, our findings demonstrate for the 
first time that, in contrast to myeloid malignancies, 
loss of 5hmC in human glioma is not caused by func-
tionally relevant TET alterations. Thus, other molec-
ular mechanisms, such as aberrant cellular TET local-
izations, inhibition of DNA accessibility or aberrant 
TET gene expressions may be responsible for the loss 
of 5hmC and the disruption of the epigenome in gli-
oma. Thus, further research addressing these new 
challenges will be necessary to understand the com-
plex mechanisms leading to the disturbed epigenomic 
landscape in human brain tumors. 
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